Rev1 Ventures, the Columbus investor startup studio that combines capital and strategic services to help startups scale and corporations innovate, is launching its second fund focused on life sciences companies. The $15 million Rev1 Catalyst Fund II with investment from The Ohio State University, Nationwide Children’s Hospital and Rev1 is three times the size of the first life sciences fund and aims to deliver critical investment capital and support for research-based spinouts and health care innovators.

As a result of the success of the Rev1 Life Sciences Fund I, this fund will continue to help Rev1 fulfill its mission to propel the creation of high-growth companies in the region.

“By aligning champions of health care innovation, including prominent research institutions like The Ohio State University and Nationwide Children’s Hospital, we are helping to foster life sciences innovation and support entrepreneurs and scientists as they build and grow new companies,” Rev1 Ventures President and CEO Tom Walker said, in a statement. “The Rev1 Catalyst Fund II is dedicated to expanding the infrastructure to support life sciences and attracting talent and like-minded investors to fuel commercialization.”

The Rev1 Life Sciences Fund I supports a portfolio of companies driving the creation of innovative therapies and solutions, and has generated more than $250 million in exits, including the recent acquisitions of Celenex and Myonexus.